We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00106340
First Posted: March 23, 2005
Last Update Posted: January 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Novartis
March 22, 2005
March 23, 2005
January 1, 2013
March 2005
May 2008   (Final data collection date for primary outcome measure)
Time to HbA1c >8% [ Time Frame: 2 year ]
Blood glucose levels
Complete list of historical versions of study NCT00106340 on ClinicalTrials.gov Archive Site
  • Change from baseline in HbA1c at 5 years [ Time Frame: 2 years (amended) ]
  • Adverse event profile after 5 years of treatment [ Time Frame: 2 years (amended) ]
  • Coefficient of failure for HbA1c from week 24 to 5 years [ Time Frame: 2 years (amended) ]
  • Change from baseline in fasting plasma glucose at 5 years [ Time Frame: 2 years (amended) ]
  • Change from baseline in body weight at 5 years [ Time Frame: 2 years (amended) ]
Not Provided
Not Provided
Not Provided
 
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: vildagliptin
    Other Name: LAF237, Galvus
  • Drug: glimepiride
  • Drug: Metformin
  • Drug: Vildagliptin matching placebo
  • Drug: Glimepiride matching placebo
  • Experimental: Vildagliptin
    Interventions:
    • Drug: vildagliptin
    • Drug: Metformin
    • Drug: Glimepiride matching placebo
  • Active Comparator: Glimepiride
    Interventions:
    • Drug: glimepiride
    • Drug: Metformin
    • Drug: Vildagliptin matching placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3118
Not Provided
May 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • On a stable dose of metformin as defined by the protocol
  • Body mass index (BMI) in the range 22-45
  • Blood glucose criteria must be met

Exclusion Criteria:

  • Pregnancy or lactation
  • Type 1 diabetes
  • Evidence of significant diabetic complications
  • Evidence of serious cardiovascular complications
  • Laboratory value abnormalities as defined by the protocol
  • Other protocol-defined exclusion criteria may apply
Sexes Eligible for Study: All
18 Years to 73 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   United States
 
 
NCT00106340
CLAF237A2308
Not Provided
Not Provided
Not Provided
External Affairs, Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP